2024-10-22 - Analysis Report
## Eli Lilly and Co (LLY) Stock Analysis Report

**Company Overview:** Eli Lilly and Co is a pharmaceutical company that researches, develops, manufactures, and markets a wide range of pharmaceutical products. 

**Performance Analysis:**

**1. Relative Performance:**

* **Cumulative Return:** LLY: 871.93%, VOO: 136.39%
* **Outperformance:** LLY has significantly outperformed the S&P 500 (VOO) with a cumulative return that is 735.54% higher. This places LLY in the 91.31% percentile of its historical performance relative to the S&P 500.

**2. Recent Price Movement:**

* **Closing Price:** $906.00
* **5-day Moving Average:** $912.73
* **20-day Moving Average:** $906.36
* **60-day Moving Average:** $903.50

The stock price is currently trading slightly below its 5-day moving average, indicating a potential short-term downward trend. However, it is trading above both the 20-day and 60-day moving averages, suggesting a longer-term bullish trend.

**3. Technical Indicators:**

* **RSI:** 56.8 (Neutral)
* **PPO:** 0.02 (Neutral)
* **Delta_Previous_Relative_Divergence:** -2.91 (Short-term downward trend)
* **Expected Return:** 48.08% (Expected long-term outperformance compared to the S&P 500)

The RSI and PPO values are neutral, indicating no clear buy or sell signals. However, the negative Delta_Previous_Relative_Divergence suggests a potential short-term pullback. Despite this, the expected return of 48.08% suggests a strong long-term investment opportunity.

**4. Recent Earnings and Outlook:**

| Date       | EPS   | Revenue         |
|-------------|-------|-----------------|
| 2024-08-08 | 3.29  | $11.30 Billion  |
| 2024-04-30 | 2.49  | $8.77 Billion  |
| 2023-11-02 | -0.06 | $9.50 Billion  |
| 2023-08-08 | 1.96  | $8.31 Billion  |
| 2023-05-09 | 1.96  | $8.31 Billion  |

The most recent earnings report (2024-08-08) showed an EPS of $3.29, exceeding analysts' expectations. Revenue also beat estimates, coming in at $11.30 billion. This strong performance reaffirms the company's consistent growth trajectory.

**5. News and Recent Issues:**

* **Positive Market Outlook:**  Analysts remain optimistic about LLY's future prospects, highlighting the company's strong drug pipeline, particularly its focus on diabetes and obesity treatment.
* **Analyst Opinions:** Most analysts have a "Buy" or "Strong Buy" rating on LLY, citing its robust earnings growth and market leadership.
* **Performance Highlights:** LLY has been consistently exceeding market expectations, driven by its innovative products and expanding market reach. 

**6. Summary:**

LLY has shown strong performance in recent years, significantly outperforming the S&P 500. The company continues to demonstrate consistent revenue and earnings growth, backed by a robust product portfolio and positive market outlook. Although technical indicators suggest a potential short-term pullback, the long-term expected return of 48.08% makes LLY an attractive investment option for those seeking strong long-term growth potential.

**7. Disclaimer:** This report is for informational purposes only and should not be considered investment advice. Always consult with a qualified financial professional before making any investment decisions. 
